Dr. Gayed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3471 5th Ave
Ste 700
Pittsburgh, PA 15213Phone+1 412-692-2031Fax+1 412-692-4101
Summary
- Dr. Bishoy Gayed is the director of urologic oncology at Saint Agnes Hospital. Dr. Gayed completed his fellowship training in urologic oncology at the University of Texas Southwestern. He specializes in the treatment and management of kidney, prostate, bladder, ureteral, testicular, penile, and adrenal cancers, including the use of robotics, laparoscopy, focal therapy, and open surgical techniques. He also focuses on urinary diversion (continent and incontinent).
Dr. Gayed has published over 25 articles, written multiple book chapters, and presented at numerous local and national meetings in the field of urologic oncology.
He typically employs a team approach to the management of his patients in which multiple physicians discuss the best treatment for the patient.
He performs surgery at St. Agnes Hospital and Baltimore Washington Medical Center. He has office locations at St. Agnes Hospital and in Columbia.
Education & Training
- UPMC Medical EducationResidency, Urology, 2008 - 2012
- Vanderbilt University Medical CenterInternship, Transitional Year, 2006 - 2007
- University of Missouri Kansas City School of MedicineClass of 2006
Certifications & Licensure
- PA State Medical License 2007 - 2024
- MD State Medical License 2014 - 2018
- TX State Medical License 2012 - 2016
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 19 citationsSmall Renal Masses in Close Proximity to the Collecting System and Renal Sinus Are Enriched for Malignancy and High Fuhrman Grade and Should Be Considered for Early In...Andres F. Correa, Amir Toussi, Milon Amin, Ronald L. Hrebinko, Bishoy A. Gayed
Clinical Genitourinary Cancer. 2018-02-05 - 15 citationsPrognostic value of tissue-based biomarker signature in clear cell renal cell carcinomaAhmed Q. Haddad, Jun Hang Luo, Laura Maria Krabbe, Oussama M. Darwish, Bishoy A. Gayed
BJU International. 2017-05-01 - 18 citationsCell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non–muscle-invasive high-grade bladder cancerNiccolo Passoni, Bishoy A. Gayed, Payal Kapur, Arthur I. Sagalowsky, Shahrokh F. Shariat
Urologic Oncology. 2016-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: